内科理论与实践2024,Vol.19Issue(4) :273-277.DOI:10.16138/j.1673-6087.2024.04.11

黄药子治疗Graves病有效性和安全性的研究进展

Study on efficacy and safety of Dioscorea bublifera L.in treatment of Graves disease

崔依帆 张瑞祥 韦晓 刘超
内科理论与实践2024,Vol.19Issue(4) :273-277.DOI:10.16138/j.1673-6087.2024.04.11

黄药子治疗Graves病有效性和安全性的研究进展

Study on efficacy and safety of Dioscorea bublifera L.in treatment of Graves disease

崔依帆 1张瑞祥 1韦晓 1刘超1
扫码查看

作者信息

  • 1. 南京中医药大学附属中西医结合医院内分泌科 江苏省中医药研究院国家中医药管理局瘿病证治重点研究室,江苏 南京 210028
  • 折叠

摘要

甲状腺功能亢进症以弥漫性毒性甲状腺肿(Graves disease,GD)最多见,传统的抗甲状腺药物往往难以取得满意的功效,复发率高、疗程长是最为突出的缺点.中药黄药子具有"消瘿"的功效,近年被广泛用于治疗GD,但长期使用可能会导致肝功能和肾功能损害.故黄药子治疗GD的有效性和安全性需更多研究.

Abstract

Hyperthyroidism is most common in Graves disease(GD),and traditional antithyroid medicine are often difficult to achieve satisfactory efficacy,and high recurrence rate and long course of treatment are the most prominent problems.Huangyaozi(Dioscorea bublifera L.),a traditional Chinese medicine,has the effect of"Xiao Ying"and has been widely used in the treatment of GD in recent years,but long-term use may cause liver and kidney damage.Therefore,more research on the efficacy and safety of Huangyaozi need to be done in the treatment of GD.

关键词

黄药子/Graves病/有效性/安全性/薯蓣皂苷元/肝毒性

Key words

Dioscorea bublifera L./Graves disease/Efficacy/Safety/Diosgenin/Hepatotoxicity

引用本文复制引用

出版年

2024
内科理论与实践
上海交通大学医学院附属瑞金医院

内科理论与实践

CSTPCD
影响因子:0.432
ISSN:1673-6087
段落导航相关论文